DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
-
PD 102807 (HB1509)
Description:Potent, selective M4 receptor antagonist. Promotes erythroid progenitors expansion.
Purity:>98%
-
Perlapine (HB4889)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator
Purity:>98%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Water soluble.
Purity:>98%
-
-
-
VU 0357017 hydrochloride (HB1498)
Description:Potent, selective M1 receptor allosteric agonist
Purity:>98%
-
Diphenhydramine hydrochloride (DPH) (HB2617)
Description:Histamine H1 antagonist. Potent actuator of a modified hM4Di "GRANPA" DREADD receptor.
Purity:>99%
